Table 2.
Gastrointestinal toxicities with IRd and placebo‐Rd
| Placebo‐Rd (n = 359) | IRd (n = 361) | |
|---|---|---|
| Nausea | ||
| Grade 1 (%) | 15 | 22 |
| Grade 2 (%) | 7 | 5 |
| Grade 3 (%)a | 0 | 2 |
| Time to documented recovery (days) | 7 | 12 |
| Vomiting | ||
| Grade 1 (%) | 8 | 17 |
| Grade 2 (%) | 3 | 6 |
| Grade 3 (%)a | <1 | 1 |
| Time to documented recovery (days) | 1 | 1 |
| Diarrhoea | ||
| Grade 1 (%) | 22 | 24 |
| Grade 2 (%) | 14 | 15 |
| Grade 3 (%)a | 3 | 6 |
| Time to documented recovery (days) | 5 | 4 |
IRd, ixazomib, lenalidomide, and dexamethasone; Placebo‐Rd, placebo plus lenalidomide and dexamethasone.
a
No grade 4 or 5 events were reported.